| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Kalvista Pharmaceuticals, Inc. (KALV) has 12 insiders with recent SEC Form 4 filings, including 10 buys and 12 sells. KALV is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 462.6K | $12.49M | - | |
| Other | 223.5K | $6.03M | - | |
| Other | 142.5K | $3.85M | - | |
| Other | 100.0K | $2.70M | - | |
| Other | 51.4K | $1.39M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Feb 5, 2020 | Crockett Thomas Andrew72 | CEO | Sell | 200 | $17.05 | $3,410.00 | - | |
| Dec 20, 2019 | Yea Christopher53 | Chief Development Officer | Sale+OE | 2,646 | $17.02 | $45,025.13 | -3.1% | |
| Dec 20, 2019 | Crockett Thomas Andrew72 | CEO | Sell | 2,300 | $17.02 | $39,150.37 | -1.0% | |
| Dec 16, 2019 | Yea Christopher53 | Chief Development Officer | Sale+OE | 4,709 | $17.05 | $80,269.34 | -1.9% | |
| Dec 16, 2019 | Crockett Thomas Andrew72 | CEO | Sell | 7,700 | $17.06 | $131,352.30 | -1.0% | |
| Sep 27, 2019 | Soland Daniel B | Director | Buy | 10,000 | $11.87 | $118,749.99 | +490.7% | |
| Jul 29, 2019 | Cha Albert | Director | Buy | 56,367 | $16.99 | $957,737.10 | +2.6% | |
| Jul 23, 2019 | Feener Edward P.72 | Chief Scientific Officer | Sell | 3,300 | $18.62 | $61,443.01 | -1.7% | |
| Jul 22, 2019 | Yea Christopher53 | Chief Development Officer | Sale+OE | 7,355 | $18.35 | $134,929.68 | -8.1% | |
| Jul 19, 2019 | Cha Albert | Director | Buy | 61,280 | $17.79 | $1,090,295.69 | +3.0% |